Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.

@article{Diehl2003StandardAI,
  title={Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.},
  author={Volker Diehl and Jeremy Franklin and Michael Pfreundschuh and Bernd Lathan and Ursula Paulus and Dirk Hasenclever and Hans Tesch and Richard Herrmann and Bernd Doerken and Hans-Konrad Mueller-Hermelink and Eckhardt D{\"u}hmke and Markus L{\"o}ffler},
  journal={The New England journal of medicine},
  year={2003},
  volume={348 24},
  pages={2386-95}
}
BACKGROUND Faced with unsatisfactory results of treatment for advanced Hodgkin's disease, we investigated three combinations of chemotherapy. METHODS From 1993 to 1998, 1201 eligible patients 15 to 65 years of age who had newly diagnosed Hodgkin's disease in unfavorable stage IIB or IIIA or stage IIIB or IV were randomly assigned to receive eight cycles of cyclophosphamide, vincristine, procarbazine, and prednisone alternating with doxorubicin, bleomycin, vinblastine, and dacarbazine (COPP… CONTINUE READING